Manufacturer of Controlled Substances; Notice of Application, 29720 [E9-14695]
Download as PDF
<![CDATA[
29720
Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices
(9780), a basic class of controlled
substance listed in schedule II.
The company plans to bulk
manufacture the above listed controlled
substance for distribution to its
customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than August 24, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14705 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT
ADMINISTRATION
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on May 1,
2009, Noramco Inc., Division of OrthoMcNeil, Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to bulk
manufacture the above listed controlled
substance for distribution to its
customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than August 24, 2009.
VerDate Nov<24>2008
16:15 Jun 22, 2009
Jkt 217001
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14704 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
Funding Opportunity Number: SGA–
09–07.
Key Dates: The closing date for receipt
of applications is July 31, 2009 via
Grants.gov. Applications may also be
submitted by mail.
Funding Opportunity Description
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on May 22,
2009, Noramco Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801, made
application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Tapentadol (9780), a basic class of
controlled substance listed in schedule
II.
The company plans to bulk
manufacture the above listed controlled
substance for distribution to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14695 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary; ‘‘Promotion of
Labor Rights and Employment in
Pakistan’’
June 17, 2009.
Bureau of International Labor
Affairs, Department of Labor.
Announcement Type: New. Notice of
Availability of Funds and Solicitation
for Cooperative Agreement
Applications. The full announcement is
posted on https://www.Grants.gov.
AGENCY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
The U.S. Department of Labor
(USDOL), Bureau of International Labor
Affairs (ILAB), announces the
availability of funds in the amount of
U.S. $1,600,000 to be awarded by
Cooperative Agreement to a qualifying
organization for the purpose of
implementing a worker rights and
employment demonstration project that
assists unemployed Pakistanis with
vocational and entrepreneurial training
to obtain employment or pursue
professions and acquire an
understanding of their fundamental
rights as workers. The project will take
place in the Federally Administered
Tribal Areas, the Northwest Frontier
Province and Baluchistan. Participants
provided with vocational training will
also receive integrated worker rights
training in order to ensure that they are
able to fully benefit from their new
skills and professions. Similarly, new
entrepreneurs may become employers
for the first time and will also receive
worker rights training to understand
their responsibilities as employers.
ILAB is authorized to award and
administer this program by the
Department of Labor Appropriations
Act, 2009, Public Law 111–08, 123 Stat.
524 (2009). The Cooperative Agreement
awarded under this initiative will be
managed by ILAB’s Office of Trade and
Labor Affairs. The duration of the
project funded by this solicitation is
three years. The start date of program
activities will be negotiated upon award
of the Cooperative Agreement, but will
be no later than September 30, 2009.
The full Solicitation for Grant
Applications is posted on https://
www.Grants.gov under U.S. Department
of Labor/ILAB. If you need to speak to
a person concerning these grants, or if
you have issues regarding access to the
Grants.gov Web site, you may telephone
Georgiette Nkpa at 202–693–4584 (not a
toll-free number).
Signed at Washington, DC this 17th day of
June 2009.
Cassandra Mitchell,
Grant Officer.
[FR Doc. E9–14648 Filed 6–22–09; 8:45 am]
BILLING CODE 4510–28–P
E:\FR\FM\23JNN1.SGM
23JNN1
]]>Agencies
[Federal Register Volume 74, Number 119 (Tuesday, June 23, 2009)]
[Notices]
[Page 29720]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-14695]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 22, 2009, Noramco Inc.,
Division of Ortho-McNeil, Inc., 500 Swedes Landing Road, Wilmington,
Delaware 19801, made application by letter to the Drug Enforcement
Administration (DEA) for registration as a bulk manufacturer of
Tapentadol (9780), a basic class of controlled substance listed in
schedule II.
The company plans to bulk manufacture the above listed controlled
substance for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such a substance, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA 22152; and must be filed no later
than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-14695 Filed 6-22-09; 8:45 am]
BILLING CODE 4410-09-P
